MoonLake Immunotherapeutics announced that it has signed a collaboration agreement with SHL Medical to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake’s Nanobody sonelokimab. SHL Medical will use its market-proven Molly modular platform technology to develop the autoinjector and provide its device development expertise, assembly guidance, and production competencies to support the drug-device project. A total of 17 combination products that leverage the Molly autoinjector technology have been approved in at least 69 countries, enabling home treatment in a wide range of therapeutic areas that require injectable medicines.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MLTX:
- MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply
- MoonLake Immunotherapeutics initiated with a Buy at Guggenheim
- MoonLake Immunotherapeutics added to Best Ideas List at Wedbush
- MoonLake price target raised to $30 from $28 at H.C. Wainwright
- MoonLake Immunotherapeutics management to meet with Piper Sandler